GPC1 and COVID-19: At acute phase, comparing between severe and non-severe groups, syndecan-1 levels [median (IQR), severe: 5.22 (1.97–5.57) ng/ml; non-severe: 1.64 (0.00–2.66) ng/ml, p < 0.05] but not glypican-1 levels [severe:2.81 (2.36–5.34) ng/ml; non-severe: 2.05 (1.10–3.06) ng/ml, p = 0.13] were significantly raised in severe COVID-19 group.